← Eichor
Condition: Carcinoma Neuroendocrine Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Carcinoma Neuroendocrine

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalised Immunotherapy Platform
Phase N/A · 3 location(s) · Melanoma Institute Australia · NCT06536257CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
Phase N/A · 1 location(s) · European Institute of Oncology · NCT07429851Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
NA · 1 location(s) · Goethe University · NCT07161310A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Phase N/A · 1 location(s) · VastBiome · NCT05037825An International Study on Pediatric Patients With Rare Tumors.
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT07072143SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Phase N/A · 55 location(s) · Insel Gruppe AG, University Hospital Bern · NCT01039922BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06041516Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followe
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06440057Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
Phase 1 · 1 location(s) · First Affiliated Hospital of Fujian Medical University · NCT06520319DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
NA · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT07458906Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Phase 1 · 10 location(s) · Circle Pharma · NCT06577987At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT07336147A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT0641368068Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
NA · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06277180IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Phase 1 · 2 location(s) · TuHURA Biosciences, Inc. · NCT06940440Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
NA · 2 location(s) · Nantes University Hospital · NCT06735560Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT00001238Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05830058TARGETed Therapy Drug MONITOring in DIGestive Oncology
NA · 29 location(s) · UNICANCER · NCT05443087Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03412877Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Can
Phase 2 · 13 location(s) · National Cancer Institute (NCI) · NCT05691465Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tu
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06630611Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.